The U.S. Government and Gavi, the Vaccine Alliance – Image for illustrative purposes only (Image credits: Pexels)
Washington – The United States has withheld hundreds of millions in congressionally approved funds from Gavi, the Vaccine Alliance, amid debates over vaccine safety protocols.[1][2] This standoff, initiated under the Trump administration, threatens to disrupt immunization programs that have reached over 1.2 billion children in lower-income countries since 2000.[1] Bipartisan senators recently urged the State Department to release the money, highlighting risks to U.S. health security from unchecked disease outbreaks abroad.
Gavi’s Mission and Proven Track Record
Gavi, the Vaccine Alliance operates as an independent public-private partnership focused on expanding access to vaccines in low- and middle-income countries. Launched in 2000, the organization has channeled nearly $29 billion into immunization efforts, excluding COVID-19 initiatives.[1] Its work targets vulnerable children, supporting vaccine procurement, health system strengthening, and market-shaping to drive down costs.
The partnership’s strategy for 2026-2030 emphasizes four goals: scaling up vaccine introductions, promoting equity in immunization, ensuring program sustainability, and fostering healthy vaccine markets.[1] Achievements include immunizing 1.2 billion children and averting 20.6 million future deaths, while generating $280 billion in economic benefits.[1] In 2024 alone, Gavi supported vaccinations for 72 million children and responded to outbreaks in multiple countries.
A History of Strong U.S. Partnership
The U.S. government joined Gavi as one of its original six donors, beginning contributions in 2001 under President Clinton.[1] Over the years, it emerged as the third-largest donor, accounting for 13 percent of total funding excluding COVAX efforts.[1] Agencies like USAID and the CDC provided technical assistance for vaccine introductions and routine immunization systems.
U.S. pledges grew steadily. The Biden administration committed $1.58 billion for 2026-2030, while annual contributions reached $300 million in fiscal year 2024.[3] During the pandemic, the U.S. donated $4 billion to Gavi’s COVAX facility, the largest single contribution, and shared millions of vaccine doses.[1] The country also held a donor government seat on Gavi’s 28-member board until the end of 2025.
| Fiscal Year | U.S. Contribution to Gavi |
|---|---|
| 2001 | $48 million |
| 2020-2023 | $1.16 billion (pledge) |
| 2024 | $300 million |
| 2026-2030 (pledge) | $1.58 billion |
This table illustrates the escalation in U.S. support, reflecting a commitment to global health that aligned with domestic interests like bolstering vaccine manufacturing.[3]
The Funding Withhold: Vaccine Safety at the Core
Tensions escalated in 2025 when Health and Human Services Secretary Robert F. Kennedy Jr. announced the U.S. would pause contributions until Gavi addressed vaccine safety issues.[1] Key concerns centered on thimerosal, a mercury-based preservative in multi-dose vials used in resource-limited settings, and whole-cell pertussis vaccines (DTPw), which offer robust protection but carry more side effects than alternatives.[4]
Despite Congress approving $300 million for both fiscal years 2025 and 2026, the administration has not disbursed the funds.[2] Officials conditioned release on Gavi developing a plan to phase out thimerosal-containing vaccines, aligning practices with those in the U.S. and Europe.[4] Gavi maintains that its portfolio follows World Health Organization recommendations based on scientific consensus, prioritizing stability and affordability in high-burden areas.[5]
Gavi responded to the June 2025 announcement by affirming its evidence-based approach and expressing hope for renewed partnership.[5] The U.S. lost its board seat eligibility at year’s end due to the funding suspension.
Congressional Pressure Mounts for Resolution
On May 4, 2026, a bipartisan group of senators, including Jeanne Shaheen, Susan Collins, Patty Murray, Mitch McConnell, and others, sent a letter to the State Department.[2] They questioned the delay in releasing $600 million and emphasized Gavi’s role in preventing outbreaks that could reach U.S. shores.
- Gavi has vaccinated over 1.1 billion children and graduated 19 countries from aid.
- It purchases more than $12.5 billion in U.S.-made vaccines and goods, supporting jobs.
- Restoring funds would regain U.S. influence on the board.
The senators argued that Gavi’s vaccines meet FDA standards and advance American strategic goals through sustainable health systems abroad.[2]
Stakes for Global Health and U.S. Interests
Gavi’s recent replenishment summit secured over $9 billion toward an $11.9 billion target for 2026-2030, but the U.S. shortfall exacerbates financing pressures.[1] Without American support, projections indicate 75 million fewer routine vaccinations for children over five years, potentially causing 1.2 million deaths.[6]
The dispute underscores broader shifts under the America First Global Health Strategy, including USAID’s dissolution and a pivot to bilateral aid.[6] Stakeholders from low-income governments to U.S. manufacturers watch closely, as resolution could reaffirm collaborative efforts against shared threats like measles and diphtheria. Whether through compromise on safety measures or redirected funding, the outcome will shape immunization equity for years ahead.
